AR and breast cancer: In this study, by integrating network pharmacology approaches with rigorous experimental validation, we have, for the first time, elucidated the mechanism by which EI effectively reverses PTX resistance in BC, specifically through targeted inhibition of the Androgen Receptor (AR)/RUNX1 signaling axis.